Fmr LLC boosted its stake in shares of Laboratory Corp. of America Holdings (NYSE:LH) by 28.9% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 879,956 shares of the medical research company’s stock after buying an additional 197,184 shares during the period. Fmr LLC owned approximately 0.87% of Laboratory Corp. of America worth $111,192,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in LH. JPMorgan Chase & Co. boosted its holdings in Laboratory Corp. of America by 14.9% during the third quarter. JPMorgan Chase & Co. now owns 1,645,798 shares of the medical research company’s stock valued at $285,845,000 after acquiring an additional 213,849 shares during the period. CI Investments Inc. raised its position in shares of Laboratory Corp. of America by 4.8% during the third quarter. CI Investments Inc. now owns 749,000 shares of the medical research company’s stock valued at $130,086,000 after buying an additional 34,550 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Laboratory Corp. of America during the third quarter valued at about $1,046,000. First Republic Investment Management Inc. raised its position in shares of Laboratory Corp. of America by 6.9% during the third quarter. First Republic Investment Management Inc. now owns 20,594 shares of the medical research company’s stock valued at $3,577,000 after buying an additional 1,325 shares during the last quarter. Finally, Fifth Third Bancorp raised its position in shares of Laboratory Corp. of America by 27.9% during the third quarter. Fifth Third Bancorp now owns 22,148 shares of the medical research company’s stock valued at $3,847,000 after buying an additional 4,832 shares during the last quarter. Institutional investors own 91.50% of the company’s stock.

In related news, Director R Sanders Williams sold 1,038 shares of the stock in a transaction dated Wednesday, February 13th. The shares were sold at an average price of $147.00, for a total value of $152,586.00. Following the completion of the transaction, the director now owns 8,924 shares of the company’s stock, valued at $1,311,828. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.74% of the company’s stock.

NYSE:LH opened at $159.61 on Thursday. Laboratory Corp. of America Holdings has a 12-month low of $119.38 and a 12-month high of $190.35. The company has a debt-to-equity ratio of 0.87, a current ratio of 1.51 and a quick ratio of 1.38. The stock has a market capitalization of $15.56 billion, a P/E ratio of 14.48, a price-to-earnings-growth ratio of 1.80 and a beta of 1.15.

Laboratory Corp. of America (NYSE:LH) last posted its quarterly earnings results on Thursday, February 7th. The medical research company reported $2.52 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.48 by $0.04. Laboratory Corp. of America had a net margin of 8.43% and a return on equity of 17.05%. The firm had revenue of $2.79 billion during the quarter, compared to analyst estimates of $2.78 billion. During the same quarter in the prior year, the business posted $2.45 earnings per share. The company’s quarterly revenue was up 1.6% compared to the same quarter last year. Equities analysts predict that Laboratory Corp. of America Holdings will post 11.22 EPS for the current fiscal year.

A number of research analysts have recently commented on LH shares. Morgan Stanley set a $177.00 price objective on shares of Laboratory Corp. of America and gave the company a “buy” rating in a research report on Thursday, December 20th. Zacks Investment Research raised shares of Laboratory Corp. of America from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. Bank of America lowered shares of Laboratory Corp. of America from a “neutral” rating to an “underperform” rating in a research report on Thursday, January 3rd. ValuEngine lowered shares of Laboratory Corp. of America from a “hold” rating to a “sell” rating in a research report on Monday, January 7th. Finally, TheStreet lowered shares of Laboratory Corp. of America from a “b-” rating to a “c+” rating in a research report on Friday, January 11th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have given a buy rating to the company’s stock. Laboratory Corp. of America currently has an average rating of “Hold” and an average price target of $175.50.

COPYRIGHT VIOLATION NOTICE: This report was first reported by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of US & international copyright and trademark legislation. The original version of this report can be accessed at https://www.watchlistnews.com/fmr-llc-boosts-stake-in-laboratory-corp-of-america-holdings-lh/2954131.html.

Laboratory Corp. of America Profile

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, LabCorp Diagnostics (LCD) and Covance Drug Development. It offers various clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually-transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests.

Read More: Candlestick

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Laboratory Corp. of America Holdings (NYSE:LH).

Institutional Ownership by Quarter for Laboratory Corp. of America (NYSE:LH)

Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.